INVO Fertility, Inc. (IVF) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. INVO Fertility, Inc. (formerly NAYA Therapeutics) is a healthcare services and technology company focused on the fertility marketplace. The company operates fertility clinics (including the Wisconsin Fertility Institute and INVO Centers) and sells the INVOcell medical device. In Q2 2025, the company divested an 80.1% majority stake in its NAYA Therapeutics (NTI) subsidiary to refocus exclusively on fertility, reclassifying NTI results as discontinued operations.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value |
|---|---|
| Total Revenue | $3,500,839 |
| Net Loss | $(22,688,444) |
| Net Loss from Continuing Operations | $(4,701,365) |
| Loss from Discontinued Operations (NTI) | $(16,452,562) |
| Cash and Cash Equivalents | $549,181 |
| Total Assets | $19,319,239 |
| Total Liabilities | $16,687,766 |
| Stockholders' Equity | $2,631,473 |
| Net Cash Used in Operating Activities | $(5,263,155) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $3.5 million (6 months 2025) from $3.4 million (6 months 2024), driven by clinic services.
- Discontinued Operations: The company recorded a significant loss of $16.5 million related to the divestiture of NTI, including a $14.6 million goodwill impairment and a $1.5 million loss on disposal. This contrasts with no discontinued operations in the prior year.
- Impairment Loss: A $1.4 million non-cash impairment loss was recognized on a non-competition agreement related to the Wisconsin Fertility Institute (WFI) acquisition settlement.
- Settlement Gain: A $714,500 gain on settlement was recognized related to the binding term sheet with Dr. Elizabeth Pritts regarding the WFI acquisition.
- Debt Extinguishment: A loss of $692,270 was recorded on debt extinguishment, primarily related to the Amended and Restated Debenture.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Pivot: Management has confirmed a strategic shift to focus exclusively on the fertility marketplace following the NTI divestiture. The company changed its name to INVO Fertility, Inc. and ticker to "IVF".
- Liquidity and Going Concern: The company reported a negative working capital of approximately $6.3 million. The independent auditor's report for the prior year included a "going concern" qualification. Management states it will need to raise additional debt or equity funding to meet liquidity needs over the next 12 months.
- Legal Contingency: A binding term sheet was signed to settle disputes with Dr. Pritts for $5 million. While a gain was recognized, the final settlement agreement is not yet executed, and future payments are contingent on funding proceeds.
- Capital Structure Changes: The company completed a 1-for-12 reverse stock split in March 2025 and a 1-for-3 reverse stock split in July 2025. It also raised approximately $8.7 million in a public offering in January 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing material weaknesses in segregation of duties and accounting resources.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $549k cash balance against the $5.3M operating cash burn and upcoming debt obligations.
- Settlement Finalization: Confirm the execution of the final $5M settlement agreement with Dr. Pritts and the impact on future cash flows.
- Debt Covenants: Review the terms of the Amended and Restated Debenture and related party notes (JAG, Decathlon) for upcoming maturity dates and potential default triggers.
- Equity Dilution: Assess the impact of the Additional Investment Right (AIR) exercised by FNL and subsequent warrant exercises on common share count.
- Going Concern Status: Monitor upcoming financing announcements to determine if the company can resolve the going concern qualification.